Complementary DNA Encoding the Human T-Cell FK506-Binding Protein, a Peptidylprolyl Cis-Trans Isomerase Distinct from Cyclophili
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
FKBP2 Antibody Cat
FKBP2 Antibody Cat. No.: 23-414 FKBP2 Antibody Western blot analysis of extracts of various cell lines, using FKBP2 antibody (23-414) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 90s. Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Human, Mouse, Rat Recombinant fusion protein containing a sequence corresponding to amino acids 22-142 IMMUNOGEN: of human FKBP2 (NP_004461.2). TESTED APPLICATIONS: IF, IHC, WB October 2, 2021 1 https://www.prosci-inc.com/fkbp2-antibody-23-414.html WB: ,1:500 - 1:2000 APPLICATIONS: IHC: ,1:100 - 1:200 IF: ,1:50 - 1:200 POSITIVE CONTROL: 1) MCF7 2) SKOV3 3) Jurkat 4) HeLa 5) Mouse thymus 6) Mouse liver PREDICTED MOLECULAR Observed: 14kDa WEIGHT: Properties PURIFICATION: Affinity purification CLONALITY: Polyclonal ISOTYPE: IgG CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: PBS with 0.02% sodium azide, 50% glycerol, pH7.3. STORAGE CONDITIONS: Store at -20˚C. Avoid freeze / thaw cycles. Additional Info OFFICIAL SYMBOL: FKBP2 FKBP-13, FKBP13, PPIase, peptidyl-prolyl cis-trans isomerase FKBP2, 13 kDa FK506-binding protein, 13 kDa FKBP, FK506 binding protein 2, 13kDa, FK506-binding protein 2, PPIase ALTERNATE NAMES: FKBP2, epididymis secretory sperm binding protein, immunophilin FKBP13, proline isomerase, rapamycin-binding protein, rotamase GENE ID: 2286 USER NOTE: Optimal dilutions for each application to be determined by the researcher. Background and References October 2, 2021 2 https://www.prosci-inc.com/fkbp2-antibody-23-414.html The protein encoded by this gene is a member of the immunophilin protein family, which play a role in immunoregulation and basic cellular processes involving protein folding and trafficking. -
Compression of Large Sets of Sequence Data Reveals Fine Diversification of Functional Profiles in Multigene Families of Proteins
Technical note Compression of Large Sets of Sequence Data Reveals Fine Diversification of Functional Profiles in Multigene Families of Proteins: A Study for Peptidyl-Prolyl cis/trans Isomerases (PPIase) Andrzej Galat Retired from: Service d’Ingénierie Moléculaire des Protéines (SIMOPRO), CEA-Université Paris-Saclay, France; [email protected]; Tel.: +33-0164465072 Received: 21 December 2018; Accepted: 21 January 2019; Published: 11 February 2019 Abstract: In this technical note, we describe analyses of more than 15,000 sequences of FK506- binding proteins (FKBP) and cyclophilins, also known as peptidyl-prolyl cis/trans isomerases (PPIases). We have developed a novel way of displaying relative changes of amino acid (AA)- residues at a given sequence position by using heat-maps. This type of representation allows simultaneous estimation of conservation level in a given sequence position in the entire group of functionally-related paralogues (multigene family of proteins). We have also proposed that at least two FKBPs, namely FKBP36, encoded by the Fkbp6 gene and FKBP51, encoded by the Fkbp5 gene, can form dimers bound via a disulfide bridge in the nucleus. This type of dimer may have some crucial function in the regulation of some nuclear complexes at different stages of the cell cycle. Keywords: FKBP; cyclophilin; PPIase; heat-map; immunophilin 1 Introduction About 30 years ago, an exciting adventure began in finding some correlations between pharmacological activities of macrocyclic hydrophobic drugs, namely the cyclic peptide cyclosporine A (CsA), and two macrolides, namely FK506 and rapamycin, which have profound and clinically useful immunosuppressive effects, especially in organ transplantations and in combating some immune disorders. -
Synthesis and Application of Light-Switchable Arylazopyrazole Rapamycin Analogs
Organic & Biomolecular Chemistry Synthesis and Application of Light-Switchable Arylazopyrazole Rapamycin Analogs Journal: Organic & Biomolecular Chemistry Manuscript ID OB-COM-08-2019-001719.R1 Article Type: Communication Date Submitted by the 25-Aug-2019 Author: Complete List of Authors: Courtney, Taylor; University of Pittsburgh, Chemistry Horst, Trevor; University of Pittsburgh, Chemistry Hankinson, Chasity; University of Pittsburgh, Chemistry Deiters, Alexander; University of Pittsburgh, Chemistry Page 1 of 11 Organic & Biomolecular Chemistry Synthesis and Application of Light-Switchable Arylazopyrazole Rapamycin Analogs Taylor M. Courtney, Trevor J. Horst, Chasity P. Hankinson, and Alexander Deiters* Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, United States [email protected] Abstract: Rapamycin-induced dimerization of FKBP and FRB has been utilized as a tool for co-localizing two proteins of interest in numerous applications. Due to the tight binding interaction of rapamycin with FKBP and FRB, the ternary complex formation is essentially irreversible. Since biological processes occur in a highly dynamic fashion with cycles of protein association and dissociation to generate a cellular response, it is useful to have chemical tools that function in a similar manner. We have developed arylazopyrazole-modified rapamycin analogs which undergo a configurational change upon light exposure and we observed enhanced ternary complex formation for the cis-isomer over the trans-isomer for one of the analogs. Introduction: Chemical inducers of dimerization (CIDs) are prominent tools used by chemical biologists to place biological processes under conditional control.1-4 The most commonly utilized CID is rapamycin, a natural product that binds to FK506 binding protein (FKBP) with a 0.2 nM Kd. -
The Immunophilins, Fk506 Binding Protein and Cyclophilin, Are Discretely Localized in the Brain: Relationship to Calcineurin
NeuroscienceVol. 62,NO. 2, pp. 569-580,1994 Elsevier Sctence Ltd Copyright 0 1994 IBRO Pergamon 0306-4522(94)E0182-4 Printed in Great Britain. All rights reserved 0306-4522194 $7.00 + 0.00 THE IMMUNOPHILINS, FK506 BINDING PROTEIN AND CYCLOPHILIN, ARE DISCRETELY LOCALIZED IN THE BRAIN: RELATIONSHIP TO CALCINEURIN T. M. DAWSON,*t J. P. STEINER,* W. E. LYONS,*11 M. FOTUHI,* M. BLUE? and S. H. SNYDER*f§l Departments of *Neuroscience, tNeurology, $Pharmacology and Molecular Sciences, and §Psychiatry, Johns Hopkins University School of Medicine, 725 N. Wolfe Street, Baltimore, MD 21205, U.S.A. (IDivision of Toxicological Science, Johns Hopkins University School of Hygiene and Public Health Abstract-The immunosuppressant drugs cyclosporin A and FK506 bind to small, predominantly soluble proteins cyclophilin and FK506 binding protein, respectively, to mediate their pharmacological actions. The immunosuppressant actions of these drugs occur through binding of cyclophilin-cyclosporinA and FK506 binding protein-FK506 complexes to the calcium-calmodulin-dependent protein phosphatase, calcineurin, inhibiting phosphatase activity, Utilizing immunohistcchemistry, in situ hybridization and autoradiography, we have localized protein and messenger RNA for FKS06 binding protein, cyclophilin and calcineurin. All three proteins and/or messages exhibit a heterogenous distribution through the brain and spinal cord, with the majority of the localizations being neuronal. We observe a striking co-localiz- ation of FK506 binding protein and calcineurin in most -
Human FKBP2 Natural ORF Mammalian Expression Plasmid
Human FKBP2 natural ORF mammalian expression plasmid Catalog Number: HG12433-UT General Information Plasmid Resuspension protocol Gene : FK506 binding protein 2, 13kDa 1.Centrifuge at 5,000×g for 5 min. Official Symbol : FKBP2 2.Carefully open the tube and add 100 l of sterile water to Synonym : PPIase, FKBP-13 dissolve the DNA. Source : Human 3.Close the tube and incubate for 10 minutes at room temperature. cDNA Size: 429bp 4.Briefly vortex the tube and then do a quick spin to concentrate RefSeq : BC003384 the liquid at the bottom. Speed is less than 5000×g. Plasmid pCMV3-FKBP2 5.Store the plasmid at -20 ℃. Description Lot : Please refer to the label on the tube The plasmid is ready for: Sequence Description : • Restriction enzyme digestion Identical with the Gene Bank Ref. ID sequence. • PCR amplification Restriction site: HindIII + XbaI (6.1kb + 0.43kb) • E. coli transformation Vector : pCMV3-untagged • DNA sequencing Shipping carrier : Each tube contains approximately 10 μg of lyophilized plasmid. E.coli strains for transformation (recommended but not limited) Storage : Most commercially available competent cells are appropriate for The lyophilized plasmid can be stored at ambient temperature for three months. the plasmid, e.g. TOP10, DH5α and TOP10F´. Quality control : The plasmid is confirmed by full-length sequencing with primers in the sequencing primer list. Sequencing primer list : pCMV3-F: 5’ CAGGTGTCCACTCCCAGGTCCAAG 3’ pcDNA3-R : 5’ GGCAACTAGAAGGCACAGTCGAGG 3’ Or Forward T7 : 5’ TAATACGACTCACTATAGGG 3’ ReverseBGH : 5’ TAGAAGGCACAGTCGAGG 3’ pCMV3-F and pcDNA3-R are designed by Sino Biological Inc. Customers can order the primer pair from any oligonucleotide supplier. -
Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase -
Tumor Growth and Cancer Treatment
Molecular Cochaperones: Tumor Growth and Cancer Treatment The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Calderwood, Stuart K. 2013. “Molecular Cochaperones: Tumor Growth and Cancer Treatment.” Scientifica 2013 (1): 217513. doi:10.1155/2013/217513. http://dx.doi.org/10.1155/2013/217513. Published Version doi:10.1155/2013/217513 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879066 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Hindawi Publishing Corporation Scientifica Volume 2013, Article ID 217513, 13 pages http://dx.doi.org/10.1155/2013/217513 Review Article Molecular Cochaperones: Tumor Growth and Cancer Treatment Stuart K. Calderwood Division of Molecular and Cellular Biology, Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Avenue, Boston, MA 02215, USA Correspondence should be addressed to Stuart K. Calderwood; [email protected] Received 11 February 2013; Accepted 1 April 2013 Academic Editors: M. H. Manjili and Y. Oji Copyright © 2013 Stuart K. Calderwood. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Molecular chaperones play important roles in all cellular organisms by maintaining the proteome in an optimally folded state. They appear to be at a premium in cancer cells whose evolution along the malignant pathways requires the fostering of cohorts of mutant proteins that are employed to overcome tumor suppressive regulation. -
FKBP2 Is Differentially Expressed in the Lymph Nodes of Patients With
FKBP2 is differentially expressed in lymph node metastasis in human breast cancer. Shahan Mamoor, MS1 [email protected] East Islip, NY USA Metastasis to the brain is a clinical problem in patients with breast cancer1-3. Between the breast and the brain reside the secondary lymphoid organ, the lymph nodes. We mined published microarray data4,5 to compare primary and metastatic tumor transcriptomes for the discovery of genes associated with metastasis to the lymph nodes in humans with metastatic breast cancer. We found that FK506 binding protein 2, FKBP2, was among the genes whose expression was most different in the lymph node metastases of patients with metastatic breast cancer as compared to primary tumors of the breast. Analysis of a separate microarray dataset revealed that FKBP2 was also differentially expressed in brain metastatic tissues. FKBP2 mRNA was present at decreased quantities in lymph node metastases as compared to primary tumors of the breast. Importantly, expression of FKBP2 in primary tumors of the breast was correlated with patient overall survival, in lymph node negative patients but not in lymph node positive patients. Modulation of FKBP2 expression may be relevant to the biology by which tumor cells metastasize from the breast to the lymph nodes and the brain in humans with metastatic breast cancer. Keywords: breast cancer, metastasis, brain metastasis, central nervous system metastasis, lymph node metastasis, FK506 binding protein 2, FKBP2, systems biology of breast cancer, targeted therapeutics in breast cancer. 1 One report described a 34% incidence of central nervous system metastases in patients treated with trastuzumab for breast cancer2. -
PERK-Mediated Expression of Peptidylglycine Α-Amidating
Soni et al. Oncogenesis (2020) 9:18 https://doi.org/10.1038/s41389-020-0201-8 Oncogenesis ARTICLE Open Access PERK-mediated expression of peptidylglycine α-amidating monooxygenase supports angiogenesis in glioblastoma Himanshu Soni1,2, Julia Bode2,ChiD.L.Nguyen3, Laura Puccio1, Michelle Neßling4, Rosario M. Piro5,6,7, Jonas Bub1, Emma Phillips1, Robert Ahrends3,8, Betty A. Eipper9,BjörnTews2 and Violaine Goidts1 Abstract PKR-like kinase (PERK) plays a significant role in inducing angiogenesis in various cancer types including glioblastoma. By proteomics analysis of the conditioned medium from a glioblastoma cell line treated with a PERK inhibitor, we showed that peptidylglycine α-amidating monooxygenase (PAM) expression is regulated by PERK under hypoxic conditions. Moreover, PERK activation via CCT020312 (a PERK selective activator) increased the cleavage and thus the generation of PAM cleaved cytosolic domain (PAM sfCD) that acts as a signaling molecule from the cytoplasm to the nuclei. PERK was also found to interact with PAM, suggesting a possible involvement in the generation of PAM sfCD. Knockdown of PERK or PAM reduced the formation of tubes by HUVECs in vitro. Furthermore, in vivo data highlighted the importance of PAM in the growth of glioblastoma with reduction of PAM expression in engrafted tumor significantly increasing the survival in mice. In summary, our data revealed PAM as a potential target for antiangiogenic therapy in glioblastoma. 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; Introduction activated by auto-phosphorylation at threonine 980 on its Glioblastoma is a highly aggressive primary brain tumor cytosolic domain. This type-I membrane protein kinase with less than 15 months of median patient survival1. -
(12) United States Patent (10) Patent No.: US 7,083,918 B2 Althoff Et Al
US007083918B2 (12) United States Patent (10) Patent No.: US 7,083,918 B2 Althoff et al. (45) Date of Patent: Aug. 1, 2006 (54) BACTERIAL SMALL-MOLECULE Abstracts, American Chemical Society, 219" ACS National THREE-HYBRD SYSTEM Meeting, San Francisco, CA, p. CHED 401 (Mar. 26-30. 2000). (75) Inventors: Eric A. Althoff, New York, NY (US); Griffith, E.C. et al. “Yeast Three-Hybrid System for Detect Virginia W. Cornish, New York, NY ing Ligand-Receptor Interactions.” Methods in Enzymology, (US) vol. 328, pp. 89-103 (2000). Dove et al., (1997) 'Activation of Prokaryotic Transcription (73) Assignee: The Trustees of Columbia University Through Arbitrary Protein-Protein Contacts' Nature in the City of New York, New York, 386:627-630 ; and. NY (US) Filman et al., (1982) “Crystal Structures of Escherichia coli and Lactobacillus casei Dihydrofolate Reductase Refined at (*) Notice: Subject to any disclaimer, the term of this 1.7. A Resolution”, The Journal of biological Chemistry patent is extended or adjusted under 35 257(22): 13663-13672. U.S.C. 154(b) by 330 days. Amara, J.F. et al. A Versatile Synthetic Dimerizer for the Regulation of Protein-Protein Interactions, Proc. Natl. Acad. (21) Appl. No.: 10/132,039 Sci. USA, 1997, 94, 10618-10623 (Exhibit 1). Austin DJ, et al. Proximity versus allostery: the role of (22) Filed: Apr. 24, 2002 regulated protein dimerization in biology. 1994. Chem Biol. 1(3): 131-6 (Exhibit 13). (65) Prior Publication Data Belshaw PJ, et al. Controlling protein association and US 2003/02O3471 A1 Oct. 30, 2003 Subcellular localization with a synthetic ligand that induces heterodimerization of proteins. -
FKBP2 CRISPR/Cas9 KO Plasmid (M): Sc-420363
SANTA CRUZ BIOTECHNOLOGY, INC. FKBP2 CRISPR/Cas9 KO Plasmid (m): sc-420363 BACKGROUND APPLICATIONS The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and FKBP2 CRISPR/Cas9 KO Plasmid (m) is recommended for the disruption of CRISPR-associated protein (Cas9) system is an adaptive immune response gene expression in mouse cells. defense mechanism used by archea and bacteria for the degradation of foreign genetic material (4,6). This mechanism can be repurposed for other 20 nt non-coding RNA sequence: guides Cas9 functions, including genomic engineering for mammalian systems, such as to a specific target location in the genomic DNA gene knockout (KO) (1,2,3,5). CRISPR/Cas9 KO Plasmid products enable the U6 promoter: drives gRNA scaffold: helps Cas9 identification and cleavage of specific genes by utilizing guide RNA (gRNA) expression of gRNA bind to target DNA sequences derived from the Genome-scale CRISPR Knock-Out (GeCKO) v2 library developed in the Zhang Laboratory at the Broad Institute (3,5). Termination signal Green Fluorescent Protein: to visually REFERENCES verify transfection CRISPR/Cas9 Knockout Plasmid CBh (chicken β-Actin 1. Cong, L., et al. 2013. Multiplex genome engineering using CRISPR/Cas hybrid) promoter: drives systems. Science 339: 819-823. 2A peptide: expression of Cas9 allows production of both Cas9 and GFP from the 2. Mali, P., et al. 2013. RNA-guided human genome engineering via Cas9. same CBh promoter Science 339: 823-826. Nuclear localization signal 3. Ran, F.A., et al. 2013. Genome engineering using the CRISPR-Cas9 system. Nuclear localization signal SpCas9 ribonuclease Nat. Protoc. 8: 2281-2308. -
Identification of Calgranulin B Interacting Proteins and Network Analysis in Gastrointestinal Cancer Cells
RESEARCH ARTICLE Identification of calgranulin B interacting proteins and network analysis in gastrointestinal cancer cells Kyung-Hee Kim1,2☯, Seung-Gu Yeo3☯, Byong Chul Yoo2, Jae Kyung Myung4* 1 Omics Core Laboratory, Research Institute, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea, 2 Colorectal Cancer Branch, Research Institute, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea, 3 Department of Radiation Oncology, Soonchunhyang University College of Medicine, Cheonan, Chungnam, Republic of Korea, 4 Department of System Cancer Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea ☯ These authors contributed equally to this work. [email protected] a1111111111 * a1111111111 a1111111111 a1111111111 Abstract a1111111111 Calgranulin B is known to be involved in tumor development, but the underlying molecular mechanism is not clear. To gain insight into possible roles of calgranulin B, we screened for calgranulin B-interacting molecules in the SNU-484 gastric cancer and the SNU-81 colon cancer cells. Calgranulin B-interacting partners were identified by yeast two-hybrid and OPEN ACCESS functional information was obtained by computational analysis. Most of the calgranulin B- Citation: Kim K-H, Yeo S-G, Yoo BC, Myung JK interacting partners were involved in metabolic and cellular processes, and found to have (2017) Identification of calgranulin B interacting proteins and network analysis in gastrointestinal molecular function of binding and catalytic activities. Interestingly, 46 molecules in the net- cancer cells. PLoS ONE 12(2): e0171232. work of the calgranulin B-interacting proteins are known to be associated with cancer and doi:10.1371/journal.pone.0171232 FKBP2 was found to interact with calgranulin B in both SNU-484 and SNU-81 cells.